Tag: regulatory approvals
U.S. Food and Drug Administration Rejects Sacituzumab Govitecan
The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...
CPhI Worldwide 2015, Antibody-drug Conjugates and Market Progression
Ahead of CPhI Worldwide 2015, CPhI expert panelist, Vivek Sharma, CEO of Pharma Solutions at Piramal, analyses the challenges in developing and manufacturing of...